Polaris Group

Polaris Group is a biopharmaceutical company dedicated to pioneering advanced therapies, with a primary focus on metabolism-related diseases. Our lead candidate drug, Pegargiminase (ADI-PEG 20), is currently in the BLA-enabling stage and clinical development phase. Pegargiminase aims to disrupt cancer cell metabolism, offering a novel approach for treating various cancers significantly affected by metabolic pathways. Our mission is to revolutionize the treatment of complex diseases such as cancer by concentrating on their metabolic basis, ultimately striving to improve patient outcomes globally.